Domperidone in the treatment of dyspepsia: a double-blind placebo-controlled study.
Domperidone, at a dosage of 20 mg t.d.s before meals, in a double-blind, crossover, placebo-controlled trial reduced the level of the symptoms of dyspepsia by 76% compared to a 16% reduction with placebo. This difference was statistically significant (p less than 0.001). Thirteen of the fourteen patients in the study preferred domperidone to placebo. Four patients in the active treatment period and one in the placebo complained of mild side-effects.
D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D004341:Drug Evaluation; D004415:Dyspepsia / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos
D001562:Benzimidazoles; D010880:Piperidines; D010919:Placebos